Viewing nowPioglerone 15mg (Pioglitazone Hydrochloride)
Pioglitazone Hydrochloride 16.53mg
Tablet · Prescription medication
Bionex Co., Ltd.

MFDS item code 200703876 · Notified 2007.04.03 · Insurance code 643100820
Improvement of glycemic control in type 2 diabetes
This medication is used as an adjunct to dietary and exercise regimens for blood sugar control in patients with Type 2 diabetes. It can be administered as a monotherapy or in combination with sulfonylureas, metformin, or insulin when other oral hypoglycemic agents are ineffective. Additionally, nutritional counseling, weight loss, and exercise should be implemented, as these therapeutic efforts are critical for maintaining the drug's effectiveness and achieving optimal results. This medication is used to improve effective blood sugar control.
This medicine is administered orally once daily, with or without food. Glycated hemoglobin reflects blood glucose levels over the preceding 2 ~ 3 months. Clinically, this medicine should be administered for an adequate period to evaluate changes in glycated hemoglobin (at least 3 months), provided that the patient's glycemic control does not worsen. 1. Monotherapy This medicine may be started at 15 mg of pioglitazone once daily as monotherapy in patients whose blood glucose is not adequately controlled by diet and exercise. If the initial dose of this medicine does not provide a sufficient effect, the dose may be increased to 30 mg once daily. Combination therapy should be considered for patients who do not respond adequately to monotherapy. 2. Combination therapy 1) Sulfonylureas: This medicine may be coadministered with a sulfonylurea; the initial dose is 15 mg once daily. When used in combination with this medicine, the current sulfonylurea may be continued at the same dosage regimen. However, if the patient develops symptoms of hypoglycemia, the sulfonylurea dose should be reduced. 2) Metformin: This medicine may be coadministered with metformin; the initial dose is 15 mg once daily. When used in combination with this medicine, the current metformin may be continued at the same dosage regimen. It is unlikely that the metformin dose will need to be adjusted because of hypoglycemia during combination therapy with this medicine. 3) Insulin: This medicine may be coadministered with insulin at a dose of 15 mg once daily. The current insulin dose may be maintained when combination therapy with this medicine is initiated. However, if a patient receiving this medicine with insulin develops symptoms of hypoglycemia or the plasma glucose concentration decreases to 100 mg/dL or below, the insulin dose may be reduced by 10 ~ 25 %. Subsequent dose adjustments should be made individually according to glycemic control. Maximum recommended dose For monotherapy or combination therapy with a sulfonylurea, metformin, or insulin, doses exceeding 30 mg once daily are not recommended. Dose adjustment is not recommended in patients with renal impairment (see Patients with renal impairment under General Precautions). Treatment with this medicine should not be initiated if, at the start of therapy, the patient has clinical evidence of active liver disease or elevated serum aminotransferase levels (ALT at least 2.5 times the upper limit of normal) (see Effects on the liver under Adverse Reactions and General Precautions). Monitoring of liver enzymes is recommended in all patients before starting treatment with this medicine and periodically thereafter.
Use is not recommended in children under 18 years of age because there is no experience with its use in this age group.
This medication helps to control blood sugar levels in patients with Type 2 diabetes and works by improving insulin resistance. During the course of treatment, caution is advised as this medication can put stress on the heart, particularly in patients with congestive heart failure or a history of congestive heart failure. Patients should be closely monitored for symptoms of heart failure such as sudden weight gain, shortness of breath, and swelling during treatment. This medication can cause fluid retention, which may worsen congestive heart failure; therefore, it should be used cautiously in patients with cardiovascular disease or swelling. Patients with active bladder cancer or a history of bladder cancer should not take this medication, and any symptoms such as hematuria or urinary disorders should be reported to a doctor immediately. Patients with impaired liver function or severe kidney dysfunction should also exercise caution while taking this medication. Women who are pregnant or may become pregnant should avoid this medication, and premenopausal women should use appropriate contraceptive methods as ovulation may be stimulated. This medication does not lower blood sugar levels when given alone and is effective only in the presence of insulin, hence it is not suitable for patients with Type 1 diabetes or diabetic ketoacidosis. Regular blood glucose and liver function tests should be conducted during treatment, and if any unusual symptoms arise, medical consultation is advised. Moreover, the risk of hypoglycemia may increase when this medication is used in conjunction with other hypoglycemic agents or insulin, so caution is necessary when combining therapies. Elderly patients or those with diminished kidney and liver function require careful monitoring while taking this medication. In the case of overdose, there is no specific antidote; thus, appropriate treatment based on symptoms is vital. Lastly, this medication has not been established for safety and effectiveness in children and should not be used in this population. This medication should be stored out of the reach of children and kept in its original container to maintain quality.
Congestive heart failure, excessive and rapid weight change, dyspnea, edema, fluid retention, inadequate blood sugar control, upper respiratory infection, headache, sinusitis, myalgia, pharyngitis, abdominal distension, weight gain, hypoglycemia, urinary tract infection, lumbago, dizziness, diarrhea, elevated serum creatine kinase, hypertension, heart failure, limb pain, chest pain, cardiovascular-related death, hospitalization due to exacerbation of congestive heart failure, emergency room visit due to congestive heart failure, cardiovascular anomalies, liver failure, diabetic macular edema with vision reduction, bladder cancer, decrease in hemoglobin, decrease in hematocrit, increased serum ALT, increased serum bilirubin, fracture, dizziness, loss of appetite, constipation, upper abdominal pain, chest pain, fatigue, weakness, dyspepsia, nausea, dyspnea, itching, chest discomfort, tremor, chills, gastrointestinal disease, epigastric discomfort, numbness, muscle rigidity, head discomfort, exacerbation of liver disease, urticaria, eczema, arthralgia, knee abnormalities, arm weakness, proteinuria, increased serum creatinine, anxiety, insomnia, drowsiness, herpes simplex, blurred vision, orthostatic hypotension, palpitations, stroke, sexual dysfunction, myocardial infarction, abdominal pain, cardiac failure
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a container that can block light and air, and precautions should be taken to avoid exposure to moisture. Additionally, it is recommended to store it at temperatures between 15 to 30 degrees Celsius, especially around room temperature of approximately 25 degrees.
White round tablet
30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowPioglitazone Hydrochloride 16.53mg
Tablet · Prescription medication
Bionex Co., Ltd.

Pioglitazone Hydrochloride 16.53mg
Tablet · Prescription medication
Celltrion Pharmaceutical Co., Ltd.

Pioglitazone Hydrochloride 33.06mg
Tablet · Prescription medication
Celltrion Pharmaceutical Co., Ltd.

Pioglitazone Hydrochloride 16.53mg
Tablet · Prescription medication
Dongwha Pharmaceutical Co., Ltd.

Pioglitazone Hydrochloride 16.53mg
Tablet · Prescription medication
Hanol Bio Pharma Co., Ltd.

Pioglitazone Hydrochloride 16.53mg
Tablet · Prescription medication
Shinpoong Pharmaceutical Co., Ltd.

Pioglitazone Hydrochloride 16.53mg
Tablet · Prescription medication
Kujoo Pharmaceutical Co., Ltd.

Pioglitazone Hydrochloride 16.53mg
Tablet · Prescription medication
Kyungdong Pharm Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.